

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



SHANGHAI JUNSHI BIOSCIENCES CO., LTD.*

上海君實生物醫藥科技股份有限公司

(a joint stock company incorporated in the People's Republic of China with limited liability)

(Stock code: 1877)

APPOINTMENT OF EXECUTIVE DIRECTOR AND NON-EXECUTIVE DIRECTOR

Reference is made to the announcements dated 30 August 2023 (“**First Announcement**”) and 22 September 2023 (the “**Second Announcement**”), and the circular dated 27 September 2023 (the “**Circular**”) of Shanghai Junshi Biosciences Co., Ltd.* (上海君實生物醫藥科技股份有限公司) (the “**Company**”) in relation to, among other things, the proposed appointment of Dr. Wang Gang (“**Dr. Wang**”) as an executive director (the “**Director**”) of the Company and Dr. Li Xin (“**Dr. Li**”) as a non-executive Director.

Unless the context otherwise requires, capitalized terms used herein shall have the same meanings as those defined in the Circular.

APPOINTMENT OF EXECUTIVE DIRECTOR

The Board is pleased to announce that resolution number 2(1) regarding the appointment of Dr. Wang as an executive Director was approved at the EGM held on 20 October 2023. The appointment of Dr. Wang as an executive Director has become effective on the date of the EGM, being 20 October 2023. Poll results of the EGM are set out in the poll results announcement of the Company dated 20 October 2023.

The biographical details and other relevant information regarding Dr. Wang are set out in the First Announcement and the Circular. As at the date of this announcement, there has been no change to such information save as otherwise disclosed in this announcement.

The Company will enter into a service contract with Dr. Wang in relation to his appointment as an executive Director for a term commencing from the date of approval of his appointment at the EGM, being 20 October 2023, and expiring on the conclusion of the third session of the Board. This term of office is determinable by either party serving on the other not less than three months' written notice, and subject to retirement by rotation and re-appointment in accordance with the Articles of Association and the Hong Kong Listing Rules. Under the terms of the service contract, the remuneration of Dr. Wang will be determined with reference to his duties and responsibilities in the Company and prevailing market conditions, and will be subject to review by the Board and the Remuneration and Appraisal Committee from time to time. Dr. Wang has not entered into nor proposed to enter into any service contracts, which fall within the meaning of Rule 13.68 of the Hong Kong Listing Rules requiring the prior approval of Shareholders at general meetings, with the Company.

Save as disclosed above, there are no other matters concerning Dr. Wang's appointment as an executive Director that need to be brought to the attention of the Shareholders nor any information required to be disclosed pursuant to the requirements of Rule 13.51(2)(h) to (v) of the Hong Kong Listing Rules.

APPOINTMENT OF NON-EXECUTIVE DIRECTOR

The Board is pleased to announce that resolution number 2(2) regarding the appointment of Dr. Li as a non-executive Director was approved at the EGM held on 20 October 2023. The appointment of Dr. Li as a non-executive Director has become effective on the date of the EGM, being 20 October 2023. Poll results of the EGM are set out in the poll results announcement of the Company dated 20 October 2023.

The biographical details and other relevant information regarding Dr. Li are set out in the Second Announcement and the Circular. As at the date of this announcement, there has been no change to such information save as otherwise disclosed in this announcement.

The Company will enter into a service contract with Dr. Li in relation to her appointment as a non-executive Director for a term commencing from the date of approval of her appointment at the EGM, being 20 October 2023, and expiring on the conclusion of the third session of the Board. This term of office is determinable by either party serving on the other not less than three months' written notice, and subject to retirement by rotation and re-appointment in accordance with the Articles of Association and the Hong Kong Listing Rules. Under the terms of the service contract, no director's fee or remuneration will be paid to Dr. Li in relation to her appointment and services as a non-executive Director. Dr. Li has not entered into nor proposed to enter into any service contracts, which fall within the meaning of Rule 13.68 of the Hong Kong Listing Rules requiring the prior approval of Shareholders at general meetings, with the Company.

Save as disclosed above, there are no other matters concerning Dr. Li's appointment as a non-executive Director that need to be brought to the attention of the Shareholders nor any information required to be disclosed pursuant to the requirements of Rule 13.51(2)(h) to (v) of the Hong Kong Listing Rules.

The Board would like to take this opportunity to extend a warm welcome to Dr. Wang and Dr. Li for joining the Board.

By order of the Board
Shanghai Junshi Biosciences Co., Ltd.*
Mr. Xiong Jun
Chairman

Shanghai, the PRC, 20 October 2023

As at the date of this announcement, the board of directors of the Company comprises Mr. Xiong Jun, Dr. Li Ning, Mr. Zhang Zhuobing, Dr. Yao Sheng, Mr. Li Cong, Dr. Zou Jianjun and Dr. Wang Gang as executive Directors; Dr. Feng Hui, Mr. Tang Yi and Dr. Li Xin as non-executive Directors; and Dr. Roy Steven Herbst, Mr. Qian Zhi, Mr. Zhang Chun, Dr. Feng Xiaoyuan and Dr. Meng Anming as independent non-executive Directors.

* For identification purpose only